Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379487 | 0.81 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2MAPTTSHRHTT | |
| SCHEMBL12568160 | 0.80 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2MAPTTSHRKDM4E | |
| SCHEMBL22528397 | 0.79 | KMT2A (0.38) | ALDH1A1SMN1; SMN2NPY5RPOLBKMT2A | |
| SCHEMBL3627847 | 0.78 | NPY5R (0.46) | SMN1; SMN2NPY5RTSHRKDM4EPOLB | |
| SCHEMBL402931 | 0.78 | NPY5R (0.46) | SMN1; SMN2NPY5RTSHRKDM4EPOLB | |
| SCHEMBL3620191 | 0.78 | NPY5R (0.46) | SMN1; SMN2NPY5RTSHRKDM4EPOLB | |
| SCHEMBL2130275 | 0.77 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2MAPTTSHRKDM4E | |
| SCHEMBL5827421 | 0.77 | CDA (0.44) | ALDH1A1SMN1; SMN2NPY5RKDM4E | |
| SCHEMBL3882849 | 0.73 | MEN1 (0.55) | ALDH1A1SMN1; SMN2MAPTKDM4EPOLB | |
| SCHEMBL8340922 | 0.73 | ADORA2A (0.39) | SMN1; SMN2NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408767-B1 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | LUNDBECK & CO AS H (DK) | 2013-07-10 | — | — | EP | disclosed |
| EP-2408767-B1 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | LUNDBECK & CO AS H (DK) | 2013-07-10 | — | — | EP | disclosed |
| US-20120101078-A1 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | H. LUNDBRCK A/S (DK) | 2012-04-26 | — | — | US | disclosed |
| US-20120101078-A1 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | H. LUNDBRCK A/S (DK) | 2012-04-26 | — | — | US | disclosed |
| EP-2408767-A2 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | H. Lundbeck A/S (DK) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010108052-A2 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010108052-A2 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101078-A1 | AMIDE DERIVATIVES AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | NPY5R, NPY1R, NPY2R | ALDH1A1 4710/4885SMN1; SMN2 3161/4885MAPT 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.